(S)-tert-butyl-1-(butylamino)-4-methyl-1-oxopentan-2-ylcarbamate (8)
Intermediate 8 was prepared according to general procedure A, by coupling BocLeuOH (5.00 g, 21.6 mmol) and butylamine (3.16 g, 43.2 mmol). The crude product was purified by silica gel flash chromatography (cyclohexane/ethylacetate from 90/10 to 50/50) to obtain intermediate 8 (5.63 g, 19.7 mmol, 91 .2%) as a colorless oil. Rf = 0.25 (cyclohexane/ethylacetate: 8/2).
δH (300 MHz; CDCl3) 6.29-6.02 (m, 1H), 4.88 (bs, 1H), 4. 15-3.95 (m, 1H), 3.24 (dd, J = 12.7, 6 .4 Hz, 2H), 1.85-1.56 (m, 3H), 1.56-1.21 (m, 13H), 1.04-0.81 (m, 9H).
tert-butyl (2S,3S)-1-((S)-1-(butylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylcarbamate (9)
Intermediate 9 was prepared according to general procedure A, by coupling intermediate 8 (5.63 g, 19 .7 mmol) deprotected according to general procedure C, with BocIleOH (5.00 g, 21.6 mmol). The 
Benzyl-4-(4-((2S,3S)-1-((S)-1-(butylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxyl)benzoate (11)
Compound 11 was prepared according to general procedure A, by coupling intermediate 9 (1.17 g, 2.93 mmol), deprotected according general procedure C, with the monobenzylester of oxybisbenzoic acid 10 6 (1.12 g, 3.22 mmol). 
N-((2S
,
N-((2S,3S)-1-(((S)-1-(butylamino)-4-methyl-1-oxopentan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)-4-(4-(((S)-4-methyl-1-oxo-1-(((S)-1-oxo-1-((3-(quinolin-4-ylamino)propyl)amino)propan-2-yl)amino)pentan-2-yl)carbamoyl)phenoxy)benzamide (7)
Compound 7 
tert-butyl (S)-(1-((2-(diethylamino)ethyl)amino)-1-oxopropan-2-yl)carbamate (21)
Intermediate 21 was prepared according to general procedure A, by coupling BocAlaOH (1.00 g, 5.29 mmol) and N,N-diethylethane-1,2-diamine (1.12 g, 9.64 mmol). The crude product was purified by silica gel flash chromatography (DCM/MeOH + 10% NH3 from 100% to 9/1) to obtain intermediate 21 (0.805 g, 2.80 mmol, 53%) as a colourless oil. Rf = 0.25 (DCM/MeOH: 9/1). 
Benzyl((S)-1-(((S)-1-((2-(diethylamino)ethyl)amino)-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (22)
Intermediate 22 
N-((2S,3S)-1-(((S
)
4,4'-oxybis(N-((2S,3S)-1-((S)-1-(butylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-yl)benzamide) (17)
Compound 17 
tert-butyl (S)-(1-((3-(diethylamino)propyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (23)
Intermediate 23 
N-((2S,3R)-1-(((S)-1-(butylamino)-4-methyl-1-oxopentan-2-yl)amino)-3-methyl-1-oxopentan-

2-yl)-4-(4-(((S)-1-((3-(diethylamino)propyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)phenoxy)benzamide (18)
tert-butyl (S)-(1-((2-(diethylamino)ethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamates (24)
Intermediate 24 was prepared according to general procedure A, by coupling BocLeuOH (3.30 g, 14.3 mmol) and N,N-diethylethane-1,2-diamine (2.07 g, 17.8 mmol). The crude product was purified by silica gel flash chromatography (DCM/MeOH from 100% to 90/10) to obtain amide 24 (2.99 g, 9.07 mmol, 63.4%) as a colorless oil.
δH ( 
Benzyl(S)-4-(4-((1-((2-(diethylamino)ethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)phenoxy)benzoate (25)
Intermediate 25 
N-((S)-1-(butylamino)-4-methyl-1-oxopentan-2-yl)-4-(4-(((S)-1-((2-diethylamino)ethyl)amino)-
4-methyl-1-oxopentan-2-yl)carbamoyl)phenoxy)benzamide (19)
Compound 19 δH (300 MHz; J = 14.8, 8.2 Hz, 2H), 5H), 1H), 4H), 2H) 
Expression of recombinant PLM II
PLM II was prepared according to the procedure previously described, with slight modifications.
Briefly, pET-3a expression plasmid containing PLM II precursor gene was transformed into BL21-(DE3) pLysS E. coli. A single colony was used to inoculate 100 mL of LB medium. The culture was grown overnight at 30 °C and 60 mL were used to inoculate 3 L of fresh LB. Cells were grown until the OD at 600 nm reached 0.4, they were then induced with IPTG at a final concentration of 1 mM. After a further 3 hours incubation, cells were harvested by centrifugation and resuspended in 100 mM Tris HCl pH 8 containing 0.2% Triton. After the addition of lysozyme (1 mg/mL), resuspended cells were incubated at 37 °C for 30 minutes. The volume was sonicated, then solid urea was added to reach the final concentration of 500 mM and the solution was stirred at room temperature for 30 minutes. Inclusion bodies were harvested by centrifugation at 16000 g for 10 minutes, then resuspended in the same buffer, stirred for 30 minutes and spun as before. Inclusion bodies were solubilized in 6 M urea, 100 mM Tris HCl pH 8.5, 32 mM ß-mercaptoethanol. Protein was refolded by dialysis against 10 L of 10 mM Tris HCl, pH 8.5. Protein concentration was determined according to the method of Bradford. Protein was diluted to the final concentration of 0.5 mg mL -1 in 50% glycerol and stored at -20 °C.
Enzyme inhibition assays
PLM II assay
Pro-PLM II was activated by addition of one tenth volume of 100 mM sodium acetate buffer pH 4.7
following by incubation at 37 °C for 90 minutes. The enzyme activity of PLM II was evaluated spectrophotometrically at 300 nm by following the cleavage of the chromogenic substrate Lys-GluPhe-Val-Phe-NPhe-Ala-Leu-Lys (where NPhe is para-nitro-phenylalanine).
Inhibitors were tested at 1-100 nM dissolved in DMSO (final concentration 1% of the sample volume 
